Conasyd1%

Conasyd 1% is indicated for the local treatment of- Fungal infections of skin: Dermatophyte infections including tinea corporis, tinea cruris, tinea manuum, tinea pedis, pityriasis Versicolor (tinea versicolor), dermal candidiasis. Erythrasma: Its activity against some Gram-positive bacteria is an added benefit in mixed infections. Vulvovaginal candidiasis (VVC).

Drugs used in Vaginal and Vulval condition, Topical Antifungal preparations

Conasyd 1% interacts with 14-α demethylase, a cytochrome P-450 enzyme that converts lanosterol to ergosterol, an essential component of the yeast membrane. In this way, Conasyd 1% inhibits ergosterol synthesis, resulting in increased cellular permeability. Conasyd 1% may also inhibit endogenous respiration, interact with membrane phospholipids, inhibit the transformation of yeasts to mycelial forms and the uptake of purine, impair triglyceride and/or phospholipid biosynthesis, and inhibit the movement of calcium and potassium ions across the cell membrane by blocking the ion transport pathway known as the Gardos channel.

Topical: Apply & massage gently into the affected & surrounding skin area once or twice a day. In intertriginous areas, apply sparingly & smoothed in well to avoid macerating effects. Duration: 1-6 weeks.Vaginal candidiasis: Adult: As 6.5% ointment: Admin intravaginally at bedtime as a single dose. Child: ≥12 yr Admin at bedtime as a single dose.

Ointment: Conasyd 1% has been found to be effective as a single-dose treatment for vulvovaginal candidiasis. Insert one applicator-full (about 4.6 g) intravaginally. Administration of Conasyd 1% just prior to bedtime may be preferred.Cream: Treatment may be once or twice daily in the morning and/or evening. Up to 6 weeks may be required for chronic hyperkeratotic tinea pedis. Suppository: One 300 mg suppository intravaginally as a single dose, preferably at bedtime; for patients who are improved but not completely cured a repeat application may be effective if administered one week later.

Hypersensitivity to Cyclosporine or to any of the excipients of Cyclosporine.

Conasyd 1% is contraindicated in individuals who have been shown to be sensitive to imidazole antifungal agents or to other components of the ointment.

Burning and itching were the most frequent side effects occurring in approximately 6% and 5% of the patients respectively. There were occasional reports (less than 1%) of other side effects including irritation, discharge, vulvar edema and swelling, vaginal pain, dysuria, nocturia, dyspareunia, dryness of vaginal secretions, desquamation.

Pregnancy Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or embryocidal or other) and there are no controlled studies in women or studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the foetus.

Conasyd 1% is intended for intravaginal administration only. Administration of Conasyd 1% just prior to bedtime may be preferred. The Conasyd 1% ointment base may interact with rubber or latex products such as condoms; therefore, use of such products within 72 hours following treatment is not recommended.

Keep below 30°C temperature, away from light & moisture. Keep out of the reach of children.

Safety and effectiveness in pregnant and diabetic patients have not been established

Drugs used in Vaginal and Vulval condition, Topical Antifungal preparations

Conasyd 1% is a topical antifungal agent. It is a broad-spectrum antifungal agent that inhibits the growth of human pathogenic yeasts. It exhibits fungicidal activity in-vitro against Candida albicans, other species of the genus Candida and against Torulopsis glabrata.

Pregnancy category C. Conasyd 1% should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, nursing should be temporarily discontinued while Conasyd 1% is administered.